Pharmacists’ Key Role in The Management of Humira Biosimilars

Originally published by our sister publication Pharmacy Practice News

The introduction of adalimumab (Humira, AbbVie) biosimilars to the US market in 2023 brought significant changes for providers, patients, and pharmacies. Since its introduction in 2002, Humira has been one of the world’s bestselling drugs for treating